# Lyell Immunopharma (LYEL): Phase 1 Data, a 43.3% Day

> Source: IndicatorStack, https://indicatorstack.com/catalysts/lyel-2026-11-04-data. Updated Nov 19, 2026, 4:35 AM ET. Prices are indicative. General market information, not a recommendation to buy or sell any security.

Lyell Immunopharma (LYEL) released to Present positive updated ronde-cel data in More than 80 patients at 9:01 AM ET on Wednesday, November 4, and the stock went from Tuesday’s $10.77 close to as high as $16.73. It finished the session +43.3% at $15.43 on 6.9 times its 20-day average volume. Here is how it traded, turn by turn, and how LiveChart’s stack read each one.

Catalyst Reaction by IndicatorStack, published Nov 19, 2026, 3:56 AM ET. NASDAQ: LYEL, Biotechnology. All times ET.

## The numbers

- +43.3% Wednesday’s close ($10.77 to $15.43, high $16.73)
- 6.9× its 20-day average volume (1.1M shares on the day)
- 9:01 AM the catalyst crossed, ET (Wednesday, before the open)
- 14.7M float, shares (8% of the float traded on Wednesday)

## How the stack read it, checkpoint by checkpoint

| Checkpoint | When | Price | 5m stack bias | Compass |
| --- | --- | --- | --- | --- |
| Before | Tue close | $10.79 | Bearish, weakening | 15m and 1h split |
| Into the open | Wed 9:30 AM | $12.25 | Bullish, strong | 15m and 1h up |
| 30 minutes in | Wed 10:00 AM | $14.02 | Bullish, weakening | 15m and 1h up |
| At the close | Wed 4:00 PM | $15.47 | Neutral | 15m and 1h up |
| Thursday’s close | Thu 4:00 PM | $15.07 | Neutral | 15m and 1h split |
| Friday’s close | Fri 4:00 PM | $14.82 | Bearish, firm | 15m and 1h split |
| Monday’s close | Mon 4:00 PM | $15.37 | Bearish, strong | 15m and 1h split |

## Timeline

### Wednesday, November 4

- 9:01 AM: To Present positive updated ronde-cel data in More than 80 patients (Press release, GlobeNewsWire)
- 9:02 AM: $80 million private placement to Advance Ronde-Cel Toward Planned BLA Submission (Press release, GlobeNewsWire)
- 9:05 AM: Current report (Form 8-K) filed (Accepted by the SEC at 9:05:07 AM ET)
- 9:10 AM: 5-minute stack bias turned bullish (at $11.24)
- 9:25 AM: Premarket high $12.25 (+13.7% from the prior close)
- 9:30 AM: Session low $12.09
- 9:30 AM: Opened at $12.09 (+12.3% from Tuesday’s $10.77 close)
- 9:35 AM: Tripwire flagged a trap at the highs (a push through resistance that failed to hold, at $14.20)
- 11:20 AM: Session high $16.73
- 12:15 PM: Tripwire flagged a trap at the lows (a push through support that failed to hold, at $14.90)
- 12:55 PM: 5-minute stack bias went neutral (at $15.33, its inputs no longer agreeing)
- 1:15 PM: 5-minute stack bias turned bullish (at $15.68)
- 3:00 PM: 5-minute stack bias went neutral (at $15.11, its inputs no longer agreeing)
- 3:55 PM: Trigger marked a long at $15.47 (Hypothetical, default settings: closed at $15.17 at 4:05 PM for −1.1R (stop))
- 4:00 PM: Closed at $15.43, +43.3% on the day (1.1M shares, 6.9× its 20-day average)
- 4:05 PM: Business highlights and financial results for the third quarter 2026 (Press release, GlobeNewsWire)
- 4:14 PM: Current report (Form 8-K) filed (Accepted by the SEC at 4:14:24 PM ET)
- 4:17 PM: Quarterly report (Form 10-Q) filed (Accepted by the SEC at 4:17:48 PM ET)

### Thursday, November 5

- 8:30 AM: 5-minute stack bias turned bullish (at $15.88)
- 9:30 AM: Opened at $15.05 (−2.5% from Wednesday’s $15.43 close)
- 9:40 AM: 5-minute stack bias went neutral (at $15.33, its inputs no longer agreeing)
- 10:20 AM: Session high $16.20
- 10:20 AM: 5-minute stack bias turned bullish (at $16.05)
- 10:55 AM: 5-minute stack bias went neutral (at $15.54, its inputs no longer agreeing)
- 11:20 AM: 5-minute stack bias turned bearish (at $15.45)
- 12:20 PM: Session low $13.69
- 2:25 PM: 5-minute stack bias went neutral (at $14.86, its inputs no longer agreeing)
- 3:50 PM: Trigger marked a short at $14.73 (Hypothetical, default settings: closed at $15.07 at 3:55 PM for −1.2R (stop))
- 4:00 PM: Closed at $15.00, −2.8% on the day (658K shares, 3.2× its 20-day average)

### Friday, November 6

- 9:30 AM: Opened at $15.75 (+5.0% from Thursday’s $15.00 close)
- 10:00 AM: Session high $16.08
- 10:35 AM: 5-minute stack bias went neutral (at $15.25, its inputs no longer agreeing)
- 10:45 AM: 5-minute stack bias turned bearish (at $15.25)
- 3:40 PM: Session low $14.75
- 4:00 PM: Closed at $14.86, −0.9% on the day (251K shares, 1.1× its 20-day average)

### Monday, November 9

- 9:30 AM: Session low $14.76
- 9:30 AM: Opened at $14.76 (−0.7% from Friday’s $14.86 close)
- 10:00 AM: 5-minute stack bias went neutral (at $15.65, its inputs no longer agreeing)
- 12:25 PM: 5-minute stack bias turned bullish (at $16.31)
- 1:10 PM: Session high $17.11
- 3:30 PM: 5-minute stack bias went neutral (at $16.19, its inputs no longer agreeing)
- 3:35 PM: Trigger marked a short at $16.09 (Hypothetical, default settings: reached $15.66 at 4:55 PM for +1.3R (trailed from the low))
- 3:40 PM: 5-minute stack bias turned bearish (at $15.87)
- 4:00 PM: Closed at $15.42, +3.8% on the day (410K shares, 1.7× its 20-day average)

## Before the catalyst (Tuesday, November 3)

Lyell Immunopharma closed Tuesday at $10.77. The 5-minute stack bias was bearish (weakening), since 12:20 PM: under VWAP 10.94 and a falling SMA, momentum down. Compass read “15m and 1h split” (15m ↘ 1h ↗ 2h ↗ 4h ↑ D ↓). Undertow: volume surge, buyers hitting the offer. Tripwire: Shorts: Avoid, resistance looks thin, buying tape on it. Its Next row read “Bounce, resistance to hold at 10.94 (VWAP)”.

Over the year before, it had traded between $7.20 and $45.00. The week before, on Monday, November 2, the company had announced to participate in November investor events at 8:00 AM ET.

## The Phase 1 data and a 43.3% session (Wednesday, November 4)

The release crossed at 9:01 AM ET, with the company’s Form 8-K accepted by the SEC at 9:05 AM. It opened at $12.09, +12.3%, and the regular session ranged from $12.09 to $16.73 before closing at $15.43. It did this on a day SPY rose 1.7% and XBI, the biotechnology ETF, rose 2.7%.

Into the open the stack read it as bullish (strong) with 2 of 2 higher timeframes up, and Undertow read “buyers in control”. Thirty minutes in, the picture had changed: price was below VWAP at $14.39 and the Next row read “Pullback, support to hold at 13.30 (slow EMA)”. By the close the 5-minute bias was neutral, while Compass still read “15m and 1h up”: the day’s trend on the 5-minute chart had turned while the higher timeframes it is measured against had not.

## The session after (Thursday, November 5)

It opened at $15.05 (−2.5%) and traded from $13.69 to $16.20, closing at $15.00, −2.8% on 658K shares, still 3.2 times its 20-day average. The 5-minute stack bias was neutral, its inputs disagreeing. Compass read “15m and 1h split” (15m ↘ 1h ↑ 2h ↑ 4h ↑ D ↗). Undertow: volume surge, buyers hitting the offer. Tripwire: Longs: Caution, heavy tape pushing against it.

## The session after (Friday, November 6)

It opened at $15.75 (+5.0%) and traded from $14.75 to $16.08, closing at $14.86, −0.9% on 251K shares, still 1.1 times its 20-day average. The 5-minute stack bias was bearish (firm), since 10:45 AM: under VWAP 15.09 and a falling SMA, momentum down and net selling. Compass read “15m and 1h split” (15m ↘ 1h ↗ 2h ↗ 4h ↗ D ↗). Undertow: volume surge, buyers hitting the offer. Tripwire: Shorts: Clean, nothing major in the way.

## The session after (Monday, November 9)

It opened at $14.76 (−0.7%) and traded from $14.76 to $17.11, closing at $15.42, +3.8% on 410K shares, still 1.7 times its 20-day average. The 5-minute stack bias was bearish (strong), since 3:40 PM: under VWAP 16.10 and a falling SMA, momentum down, net selling and trend strength with the sellers. Compass read “15m and 1h split” (15m ↓ 1h ↗ 2h ↗ 4h ↗ D ↑). Undertow: volume surge, sellers hitting the bid. Tripwire: Shorts: Clean, nothing major in the way.

After hours it last traded at $15.42, with Undertow reading “sellers in control”.

## Supply

|  |  |  |
| --- | --- | --- |
| Shares outstanding | 24.6M | as reported to the SEC |
| Float | 14.7M | 60% of shares outstanding |
| Reverse splits on record | 1 | 1-for-20 reverse split, June 2, 2025 |
| Last insider purchase | November 4, 2026 | 2.3M shares at $10.77 by ARCH Venture Partners IX, LLC (10 percent owner) |
| Last insider sale | November 10, 2026 | 129 shares at $15.93 |

## Sources

- Wed Nov 4, 4:17 PM ET, SEC filing: Quarterly report (Form 10-Q) (SEC EDGAR) https://www.sec.gov/Archives/edgar/data/1806952/000162828026070171/lyel-20260930.htm
- Wed Nov 4, 4:14 PM ET, SEC filing: Current report (Form 8-K) (SEC EDGAR) https://www.sec.gov/Archives/edgar/data/1806952/000162828026070161/lyel-20261104.htm
- Wed Nov 4, 4:05 PM ET, Press release: Business highlights and financial results for the third quarter 2026 (GlobeNewsWire) https://www.globenewswire.com/news-release/2026/11/04/3395800/0/en/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-third-quarter-2026.html
- Wed Nov 4, 9:05 AM ET, SEC filing: Current report (Form 8-K) (SEC EDGAR) https://www.sec.gov/Archives/edgar/data/1806952/000119312526446317/d158628d8k.htm
- Wed Nov 4, 9:02 AM ET, Press release: $80 million private placement to Advance Ronde-Cel Toward Planned BLA Submission (GlobeNewsWire) https://www.globenewswire.com/news-release/2026/11/04/3395403/0/en/lyell-immunopharma-announces-80-million-private-placement-to-advance-ronde-cel-toward-planned-bla-submission.html
- Wed Nov 4, 9:01 AM ET, Press release: To Present positive updated ronde-cel data in More than 80 patients (GlobeNewsWire) https://www.globenewswire.com/news-release/2026/11/04/3395393/0/en/lyell-immunopharma-to-present-positive-updated-ronde-cel-data-in-more-than-80-patients-at-ash-2026-from-pinacle-pivotal-trial-in-3l-and-from-phase-1-2-2l-cohort-in-patients-with-re.html

## Questions

### Why did LYEL stock go up on November 4?

Lyell Immunopharma (LYEL) released to Present positive updated ronde-cel data in More than 80 patients at 9:01 AM ET on Wednesday, November 4, and the stock went from Tuesday’s $10.77 close to as high as $16.73. It finished the session +43.3% at $15.43 on 6.9 times its 20-day average volume. The reaction describes the sequence and infers no cause.

### What did Lyell Immunopharma announce on November 4, 2026?

Lyell Immunopharma (LYEL) released to Present positive updated ronde-cel data in More than 80 patients at 9:01 AM ET on Wednesday, November 4. The company’s release and its Form 8-K are linked in the sources on this page.

### How did LYEL stock trade on November 4?

LYEL opened at $12.09, +12.3% from the prior close of $10.77, traded between $12.09 and $16.73 in the regular session and closed at $15.43, +43.3%, on 1.1M shares.

### How did LiveChart’s stack read LYEL at the close on November 4?

At the 4:00 PM ET close the 5-minute stack bias on LYEL was neutral, Compass read “15m and 1h up” and Undertow read “volume surge”. Each turn of the read is on this page’s timeline.

### What does LiveChart’s stack read on LYEL now?

The read on this page is fixed at each moment it describes. LiveChart reads LYEL on every bar as it trades: open it on LiveChart for the current stack bias, levels and every layer.

Chart: https://indicatorstack.com/chart/LYEL. LYEL catalyst history: https://indicatorstack.com/catalysts/stock/LYEL

Each reaction describes what happened and when, infers no cause and takes no view on what comes next. Past reactions don’t predict future ones.

---

IndicatorStack: on-chart analysis for active traders. LiveChart (https://indicatorstack.com/chart) reads every bar of any US-listed ticker into one held stack bias, the levels to watch and Compass, free. Site guide: https://indicatorstack.com/llms.txt. Today's digest: https://indicatorstack.com/llms-full.txt. Risk Disclosure: https://indicatorstack.com/risk
